About Event

Welcome to the 11th Annual Tumor Models Summit

The Tumor Models Boston, stands out as the only industry-led meeting dedicated to preclinical and translational oncology, with real-world case studies that will empower you to advance your targeted combination oncology candidates to patients with optimized translatability, efficiency, and cost-effectiveness.

With the FDA Modernization Act 2.0 enabling non-animal models to be integrated into drug pipelines, newer models emerging and more combination therapies gaining approval, the tumor model space is energized with innovations. As the combination, targeted oncology industry continues to grow, the need for more clarity on best practice also increases to ensure you don’t fall behind.

The 11th annual event returned to Boston in 2023 to provide an update on tumor model advancements, and how they can complement existing models to increase clinical confidence and clinical relevancy. We accelerated the discussions on bench-to-bedside development for safe and efficacious combination partner selection.

With 2 dedicated streams for preclinical and translational scientists, here’s what’s 2023 included:

https://tumor-models.com/wp-content/uploads/sites/65/2022/03/cropped-HW220228-Tumor-Models-For-for-Combination-Targeted-Oncology-Logo-ICON-ONLY.jpg

Drug Developers and Academics - Free Attendance: Supported your translational study and pipeline progression, and offer you the opportunity to meet model providers to select the right platforms and hence, drug developers and researchers are eligible for complimentary passes

https://tumor-models.com/wp-content/uploads/sites/65/2022/03/cropped-HW220228-Tumor-Models-For-for-Combination-Targeted-Oncology-Logo-ICON-ONLY.jpg

Gain high-level insights into newer models: Dove into strategies to accurately recapitulate tumor heterogeneity and tumor microenvironment from PDX, primary patient samples through to tumoroid models

https://tumor-models.com/wp-content/uploads/sites/65/2022/03/cropped-HW220228-Tumor-Models-For-for-Combination-Targeted-Oncology-Logo-ICON-ONLY.jpg

Networking: Gave the unique opportunity to exchange challenges, inspire solutions with leading industry experts across dedicated speed-networking sessions as well as assess the latest technologies over the last 12 months

https://tumor-models.com/wp-content/uploads/sites/65/2022/03/cropped-HW220228-Tumor-Models-For-for-Combination-Targeted-Oncology-Logo-ICON-ONLY.jpg
https://tumor-models.com/wp-content/uploads/sites/65/2022/03/cropped-HW220228-Tumor-Models-For-for-Combination-Targeted-Oncology-Logo-ICON-ONLY.jpg

Novel topics: Dived into brand-new insights covering linking biomarker endpoints to accurately predict efficacy to implementing computational approaches to improve translatability across the board

Form meaningful partnerships: Meet and networked with selected CROs, model developers and academics to hear their latest platforms that will optimize your workflows

Be part of this growing community next year to support your pipeline acceleration, and develop a novel, safe and efficacious treatments for patients in need!

Want to learn more? Download the 2023 agenda here!